bioRxiv Science⌕ Search

Biology subjects

Astourian, M.

Publications and source records attributed to Astourian, M..

2 recordsLinked to original sources

Toxin resistance in the monarch butterfly expanded its milkweed host range

A central problem in ecology and evolution is to understand the extent to which herbivorous insect host plant specialization has been shaped by bottom-up natural selection from host-plant chemical defenses or top-down natural selection from natural enemies. Here, we show that the stepwise evolution of ATP target-site insensitivity (TSI) in the monarch butterfly lineage consistently tracked a dietary association with cardenolide-defended Asclepias host plants. We further show that Drosophila melanogaster flies edited with CRISPR-Cas9 genome engineering to carry the monarch butterflys more derived ATP genotype maintain survival across Asclepias host-plant diets that span a broad cardenolide defense gradient, whereas flies carrying early-diverging ATP genotypes in the monarch lineage show lower survival. We conclude that a resistance trait linked to sequestration and enemy protection also expanded dietary resistance to highly defended host plants, revealing how a single molecular adaptation may have been driven by both top-down and bottom-up selective pressures during herbivore specialization.

evolutionary biology↗

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy

Checkpoint inhibitor (ICI) immunotherapy leverages the bodys own immune system to attack cancer cells but leads to unwanted autoimmune side effects in up to 60% of patients. Such immune related adverse events (IrAE) may lead to treatment interruption, permanent organ dysfunction, hospitalization and premature death. Thyroiditis is one of the most common IrAE, but the cause of thyroid IrAE remains unknown. Here we present a novel mouse model in which checkpoint inhibitor therapy leads to multi-organ autoimmune infiltrates and show that activation and infiltration of Type 3 immune cells including IL17A+ ROR{gamma}t+ CD4+ (T helper 17 or Th17) and gamma delta 17 ({gamma}{delta}T17) T cells promote thyroid IrAE development. IL-17A+ T cells were similarly found in thyroid specimens from cancer patients treated with ICI who developed thyroid IrAE. Furthermore, antibody-based inhibition of IL-17A, a clinically available therapy, significantly reduced thyroid IrAE development in ICI-treated mice. Finally, combination of IL-17A neutralization with ICI treatment in multiple tumor models did not reduce ICI anti-tumor efficacy. These studies suggest that targeting Th17 and {gamma}{delta}17 function may reduce IrAE without impairing ICI anti-tumor efficacy and may be a generalizable strategy to address IL17-mediated IrAE.

immunology↗